Cardiology Topics
RSSArticles
-
What Causes MINOCA?
A systematic imaging protocol of coronary angiography, optical coherence tomography, and cardiac MRI in women clinically diagnosed with myocardial infarction with non-obstructive coronary artery disease revealed a cause in 84%, with three-quarters exhibiting an ischemic etiology.
-
Must-Have Documentation if ‘Low-Risk’ Chest Pain Patient Is Discharged from ED
Documenting an assessment with a validated scoring system and ensuring the timing of troponins is appropriate can reduce risk.
-
Rhythm vs. Rate Control for Atrial Fibrillation Patients: The Controversy Continues
Early use of rhythm control in patients with atrial fibrillation and high cardiovascular risk appears to improve cardiovascular outcomes compared to usual care.
-
Treating Hypertension Without Drugs
High flavanol intake was associated with lower blood pressure in men and women comparable to what is seen with a Mediterranean diet or moderate salt restriction.
-
USPSTF Refrains from Definitive Blood Pressure Screening Recommendation
Panel says more research needed before clear judgments for or against screening children, adolescents can be made.
-
Flu Shot Can Reduce Adverse Heart Outcomes
Those with heart disease can lower their risk of death or other serious complications by receiving the influenza vaccine.
-
Veterans with PTSD, TBI at Much Higher Risk for Heart Attack
Such patients also more likely to experience first attack at a younger age than the general population.
-
Using Sacubitril/Valsartan to Treat Heart Failure with Preserved Ejection Fraction
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.
-
The Effect of Age on Cholesterol-Lowering Therapy
Investigators analyzed data on the effect of age on cardiovascular (CV) outcomes and LDL cholesterol-lowering by alirocumab vs. placebo in recent acute coronary syndrome patients. They found alirocumab can lower the rate of CV events regardless of age — and produce increasing absolute benefit with age.
-
Another Affirmation for Rhythm Control in Atrial Fibrillation
A rhythm control strategy implemented less than one year after atrial fibrillation diagnosis was associated with significant reduction in adverse cardiovascular outcomes when compared to usual care.